Friday 12 August, Afternoon Tea 1530 – 1600hrs

Sessions will start around 1535hrs

Medtronic

Emerging options to manage uncontrolled hypertension: An update
Speaker: Sharad Shetty (WA)
Theatrette 2

Sanofi

LIVE Debate: Managing symptomatic CHD: “Treat the plaque” Vs “Treat the patient”
Team Plaque: Stephen Nicholls (VIC) and Matthew Worthley (SA)
Team Patient: David Colquhoun (QLD) and Brett Forge (VIC)
Adjudicators: Karam Kostner, Chair (QLD), Gemma Figtree (NSW) and Warrick Bishop (TAS)
Theatrette 3

 

Saturday 13 August, Morning Tea 1000 – 1030hrs

Sessions will start around 1005hrs

Novartis

Lp(a) – what is it, who to test and why
Speaker: Karam Kostner (QLD)
Theatrette 5


Saturday 13 August, Morning Tea 1030 – 1100hrs (ANZET)

Sessions will start around 1035hrs

Abbott

See Simply. Act Decisively’, ANZ launch of Ultreon™ 1.0 Software, powered by AI
Speaker: Scott Harding (NZ)
Intra Cardiac Echo in Structural Heart Interventions
Speaker: Tony Walton (VIC)
Theatrette 1

Bio-Excel

The Role of Heterotopic CAVI using TricValve for Tricuspid Regurgitation and other
Congenital Heart Diseases
Speaker: David Muller (NSW)
Theatrette 2

Medtronic

Emerging options to manage uncontrolled hypertension: An update
Theatrette 3

Saturday 13 August, Afternoon Tea 1500 – 1530hrs

Sessions will start around 1505hrs

AstraZeneca

Appropriate use of P2Y12 post-Acute MI. Are we doing the right thing?”
Speaker: Sidney Lo (NSW)
Theatrette 2

Novartis

Assessing the CRR performance of Entresto in the real world
Speaker: Christopher Hayward
A visual guide to cardiac remodelling (3D/4D echo or cardiac
MR or cardiac CT)
Speaker: Nicole Bart (NSW)
Theatrette 5